Results 111 to 120 of about 10,024 (235)

Strategic Preparedness of Broad‐Spectrum Antivirals for Rapid Response Towards Next Pandemics

Small Science, Volume 6, Issue 1, January 2026.
Nanoengineered broad‐spectrum antivirals (BSAs) represent a transformative approach to pandemic preparedness. Unlike virus‐specific drugs requiring separate development, BSAs act across multiple viral families through nanoengineering strategies that enhance solubility, bioavailability, and host‐targeted activity.
Sanoj Rejinold N, Geun‐woo Jin, Jin‐Ho Choy   +2 more
wiley   +1 more source

Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in High-Risk Older Adults in Japan. [PDF]

Pharmacoecon Open
This analysis aimed to evaluate the cost effectiveness of molnupiravir versus best supportive care for the treatment of older adult patients (aged ≥ 65 years) in Japan with mild to moderate COVID-19 who are at risk of disease progression leading to ...
Goswami H, Tajima A, Matsuki T, Puenpatom A.   +3 more
europepmc   +2 more sources

A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019 [PDF]

BackgroundTo address the need for treatments for patients with coronavirus disease 2019 (COVID-19), 3 therapies have been given either full approval or Emergency Use Authorization.
Haslam, Alyson, Prasad, Vinay
core   +1 more source

Inhaled Ciclesonide for Community‐Based COVID‐19: A Placebo‐Controlled Randomised Trial

Respirology, Volume 31, Issue 1, Page 82-90, January 2026.
We undertook a double‐blind, placebo‐controlled, randomised community trial of inhaled ciclesonide 320 mcg daily or placebo for 14 days. The primary outcome was time to recovery of symptoms to day 28. There were 189 people randomised and 185 completed treatment; 96% were COVID‐19 vaccinated.
Peter Wark, Ian C. Marschner, Owen Hutchings, Gemma Blunt, Greg J. Fox, Meg Jardine, Thomas Snelling, Arlen Wilcox, Emily Amico, Karen Allison, Kate Wilson, John Simes, Guy B. Marks   +12 more
wiley   +1 more source

Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens

iScience
Summary: Direct acting antivirals (DAAs) represent critical tools for combating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that have escaped vaccine-elicited spike-based immunity and future coronaviruses with ...
Irfan Ullah, Fanny Escudie, Ivan Scandale, Zoela Gilani, Gabrielle Gendron-Lepage, Fleur Gaudette, Charles Mowbray, Laurent Fraisse, Renée Bazin, Andrés Finzi, Walther Mothes, Priti Kumar, Eric Chatelain, Pradeep D. Uchil   +13 more
doaj   +1 more source

Successful Treatment of Multiple Myeloma Complicated With SARS‐CoV‐2 Infection: A Case Report

Case Reports in Medicine, Volume 2026, Issue 1, 2026.
Background Since the declaration of the coronavirus disease 2019 (COVID‐19) pandemic in late 2019, COVID‐19 has remained a global concern. Elderly patients with hematological malignancies are immunocompromised and thus highly susceptible to COVID‐19 infection and severe acute respiratory syndrome (SARS), posing significant clinical challenges.
Yuna Meng, Baoying Duan, Lixian Gao, Wenjiao Huang, Fang Wan, Poulami Jha   +5 more
wiley   +1 more source

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial [PDF]

BACKGROUND: The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of SARS-CoV-2, has not been established in vaccinated populations.
Ahmed, Haroon, Butler, Christopher C, Butler, Daniel, Carson-Stevens, Andrew, Coates, Maria, Cureton, Lucy, Dobson, Melissa, Dorward, Jienchi, Evans, Philip, Francis, Nick, Gbinigie, Oghenekome Abisoye, Grabey, Jenna, Harris, Victoria, Hart, Nigel David, Hayward, Gail, Hobbs, Fd Richard, Holmes, Jane, Hood, Kerenza, Jani, Bhautesh Dinesh, Khoo, Saye, Little, Paul, Lown, Mark, McKenna, Micheal, Mort, Sam, Nguyen-Van-Tam, Jonathan, Petrou, Stavros, Png, May Ee, Rahman, Najib, Richards, Duncan B, Thomas, Nicholas, van Hecke, Oliver, Yu, Ly-Mee   +31 more
core   +2 more sources

A cost-effectiveness analysis of Molnupiravir and Paxlovid for outpatient treatment of COVID-19 in three African countries. [PDF]

J Public Health Afr
Background Two COVID-19 oral antivirals (COAVs), Molnupiravir and Paxlovid, have been shown to be cost-effective in high-income countries. Aim This study assesses the cost-effectiveness of Paxlovid and Molnupiravir, compared to usual care in three ...
Edoka IP, Drake T, Baker P, Tajudeen R, Asfaw E, Guzman J, Ndembi N, Nonvignon J, Kaseya J.   +8 more
europepmc   +2 more sources

Full factorial design assisted RP-UHPLC method development and study of stressed degradation of molnupiravir [PDF]

To combat the SARS-CoV-2 addition of molnupiravir into the current therapeutic regimen has added new hopes. But currently, not so many analytical methods are available for analyzing molnupiravir.
Faruk, Omar, Kumar, Uttom, Lira, Dilshad Noor, Rouf, Abu Shara Shamsur, Shill, Diponkor Kumar   +4 more
core   +1 more source

GS-441524 and molnupiravir are similarly effective for the treatment of cats with feline infectious peritonitis

Frontiers in Veterinary Science
Although not registered for feline infectious peritonitis (FIP) in Japan, nucleoside analogs have shown efficacy and we have been offering them to owners of cats with FIP at our clinic since January 2020. The aim of this study was to investigate outcomes
Okihiro Sase, Tomoko Iwami, Takeru Sasaki, Tadashi Sano   +3 more
doaj   +1 more source